Dyne Therapeutics is a pre-revenue clinical-stage biotech advancing muscle disease therapies, with R&D spending surging 51% sequentially to $152.2M in Q2 2026 as it prepares for BLA submission and expanded trials.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$1.06-16.8% vs -$0.91 | — vs — |
Q3 2026 Jul 30, 2026 | -$1.08-44.2% vs -$0.75 | — vs — |
Q2 2026 May 11, 2026 | -$0.73+5.5% vs -$0.77 | — vs — |
Q2 2026 Mar 2, 2026 | -$0.76-2.7% vs -$0.74 | — vs — |
- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 -
WALTHAM, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 16 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).
- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Benchmark DYN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Dyne Therapeutics, Inc. (DYN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.07 | $3.37B | -5.43 | — | — | -69.73% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — |
Dyne Therapeutics, Inc. (DYN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Dyne Therapeutics, Inc. (DYN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 22, 2026·SEC
Jul 20, 2026·SEC
Get notified when DYN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Dyne Therapeutics, Inc. (DYN) stock FAQ — growth, dividends, profitability & financials explained
No. Dyne Therapeutics, Inc. (DYN) reported a net loss of $604.9M over the trailing twelve months.
Dyne Therapeutics, Inc. (DYN) had a return on equity (ROE) of -69.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Dyne Therapeutics, Inc. (DYN) had negative free cash flow of $568.8M over the trailing twelve months.
